Last year I wrote a piece on how the CSL Limited (ASX: CSL) share price could have turned a $1,000 investment into over $200,000 in 22 years.
Today, CSL Limited is a formidable company. A cash generating machine. But it took time. CSL evolved through decades of research and development (R&D) investment, medical advancement and growing demand. It?s important that we recognise that.
By repeatedly capitalising on core competencies, year-in, year-out, the company has compounded returns at rates far above the market average and added billions of dollars to investor?s wealth. That?s pretty cool.
I use CSL as a benchmark for…
To keep reading, enter your email address or login below.
Today, CSL Limited is a formidable company. A cash generating machine. But it took time. CSL evolved through decades of research and development (R&D) investment, medical advancement and growing demand. It’s important that we recognise that.
By repeatedly capitalising on core competencies, year-in, year-out, the company has compounded returns at rates far above the market average and added billions of dollars to investor’s wealth. That’s pretty cool.
I use CSL as a benchmark for prospective investments across a range of sectors and it’s exciting to see many of the same characteristics emerging in mask and breathing device producer Fisher & Paykel Healthcare Corp Ltd (ASX: FPH).
Here’s a quick look at how Fisher & Paykel Healthcare has been growing over the last 10 years:
There’s a lot to like in that simple chart. First there’s consistent, long-term revenue growth which has more than doubled over the last 10 years.
Fisher & Paykel Healthcare reinvests about 10% of annual revenue on R&D, resulting in new product lines and better quality. This is a similar rate to CSL Limited which invests around 9% of annual revenue in R&D.
The second thing to like is the growing operating margin. The lift has come from lower manufacturing costs as the company shifted some of its production from Mexico and closer to its biggest market of North America.
You don’t need me to spell out how valuable that is, but I will for emphasis: the combination of revenue growth and higher operating margins is absolute rocket fuel for profitability and investor returns. Not only is the company earning more, but it’s keeping more, and able to reinvest more for the future.
The next CSL Limited?
With a current market capitalisation of just under $6 billion, Fisher & Paykel Healthcare is about one-tenth the size of CSL Limited, but I see similarities in the way the companies operate and a promising future for Fisher & Paykel Healthcare.
I would expect operating margin growth to slow over the coming years as cost efficiencies are reached, but with minimal debt and a strong demand outlook I’m excited for Fisher & Paykel Healthcare’s future.
This company's dividend is almost the stuff of legends. Since it started paying dividends in 2007, it has increased its payout to shareholders every single year, a run that includes 21 consecutive dividend increases.
Based on the last 12-months of dividends, its shares are currently offering a fully-franked 4.8% yield, which grosses up to almost 7% when those franking credits are included. And in stark contrast to the likes of Commonwealth Bank and Telstra, this company just increased its dividend by over 13%, and guided for 2017 profits to grow by 20%!
Discover the name of this "new breed" of blue chip along with 2 others in our new FREE report "The Motley Fool's Top 3 Blue Chips Stocks For 2017."
Click here to receive your copy.
Motley Fool contributor Regan Pearson has no position in any stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.